Integrative multi-omics analysis uncovers tumour-immune-gut axis influencing immunotherapy outcomes in ovarian cancer
About 50% of all ovarian cancer has an increased T cell infiltration suggesting a strong immune response. This is associated with good survival.
Targeted immune therapy which inhibits checkpoint activity unfortunately thus far has not been shown to be effective against ovarian cancer. This study looked at the impact of the faecal microbiome on immune checkpoint blockade (ICB).
Using data from another study, which tested the effect of ICB for recurrent ovarian cancer, a subgroup of patients showed a significant benefit (30%). These patients had a different microbiome when compared to those patients who did not have much benefit.
This information suggests that manipulation of the gut biome could be an aid to survival for patients with recurrent ovarian cancer.
No comments:
Post a Comment